Core Viewpoint - CalciMedica Inc. is set to present the full data set and win ratio analysis from its Phase 2b CARPO trial of Auxora™ for acute pancreatitis with systemic inflammatory response syndrome on October 30, 2024 [1] Group 1: Company Overview - CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases [3] - The company's lead product candidate, Auxora™, has shown positive clinical results in multiple completed efficacy trials [3] - CalciMedica has completed a Phase 2 trial (CARDEA) in patients with COVID pneumonia and is conducting a Phase 2 trial (KOURAGE) in patients with acute kidney injury [3] Group 2: Upcoming Event Details - A conference call and webcast will be held on October 30, 2024, at 12 p.m. ET/9 a.m. PT to discuss the CARPO trial results [1] - The event will feature a plenary presentation by Prof. Robert Sutton from the University of Liverpool [1] - Interested parties can access the live webcast through CalciMedica's investor relations website [1][2]
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)